MELISSA WILLIS: Open Payments
NPI 1629021357 · MARTINSVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$622 in 21 payments from 12 companies in 2025. Trend: 2023 $1,267 · 2024 $1,241 · 2025 $622
Food & beverage: $622
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 4 | $129 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Janssen Biotech, Inc. | 2 | $85 |
| Novartis Pharmaceuticals Corporation | 3 | $64 |
| Eisai Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| GlaxoSmithKline, LLC. | 2 | $31 |
| Gilead Sciences, Inc. | 1 | $23 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| PFIZER INC. | 1 | $20 |
Products named: Xtandi, Lenvima, SCEMBLIX, RYBREVANT, DARZALEX, Padcev, ZEJULA, FRUZAQLA.
Industry payments across IN — which companies pay providers there.
